No Data
Beijing Tiantan Biological Unit's Clinical Trial on Immunodeficiency Drug Shows Positive Results
Express News | Beijing Tiantan Biological Products Corporation: The subcutaneous injection of human immunoglobulin has completed phase III clinical trials.
Beijing Tiantan Biological Products Corporation (600161): Third quarter performance fluctuations do not hinder the annual performance targets.
Event: The company released the 2024 third-quarter report, achieving an annual revenue of 4.07 billion yuan, +1.3% year-on-year, achieving a net income attributable to the parent company of 1.05 billion yuan, +18.5% year-on-year, and a net income attributable to the parent company excluding non-recurring gains and losses of 1.04 billion yuan, year-on-year.
Beijing Tiantan Biological Products Corporation (600161): Profitability enhanced, license expansion helps to open up new sources for plasma collection.
The company released its 2024 third-quarter report: In the first three quarters of 2024, it achieved revenue of 4.073 billion yuan, net income attributable to the mother 1.052 billion yuan, non-net profit attributable to the mother 1.044 billion yuan, year-on-year growth of 1.28% respectively.
Beijing Tiantan Biological Products Corporation (600161.SH): The "Human Prothrombin Complex" developed has completed clinical ethical review, pre-clinical preparation for inclusion and other work, and officially started phase III clinical trials recently.
Gelonghui October 31st news | beijing tiantan biological products corporation (600161.SH) announced that the "Human Prothrombin Complex" developed by its subsidiary guizhou biological pharmaceutical co., ltd. of China National Pharmaceutical Group has completed the clinical ethical review, pre-clinical recruitment preparation, and officially launched phase III clinical trials in recent days.
Earnings Beat: Beijing Tiantan Biological Products Co., Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
No Data
